IFNB1 and neoplasm: The systemic format of VV1 therapy was not chosen by chance: when delivered via such a route to patients with metastatic solid and hematological tumors, VV1 infects tumor cells and macrophages in the lymph nodes and spleen, leading to the release of tumor antigens and IFN-β, which activates and enhances cellular anti-tumor immunity.